Recent studies have confirmed that immunophenotyping based on CD8+ T cell infiltration and PD-L1 expression in the intratumoral region is a better choice for predicting the efficacy of NSCLC immunotherapy, but there are no related reports on PSC (17). Here, CD8A is linked to non-small cell lung carcinoma.